The project entitled “INNODIAG” focuses on two complementary axes. On one hand; it deals with the selection and validation of new biomarkers genes in the treatment of breast cancer through the application of novel learning methods using fuzzy logic developed by the group DISCO LAAS. This tool used for the first time on data sets of tumors of breast cancer was found to have a gain rose 10% on the reliability of prognosis compared to those obtained by other existing tests, including in particular the using DNA microarray "Mammaprint®” fabricated with 70 genes selected by methods of hierarchical classification. Alongside this work, a prototype next-generation microarray, designed by the application of innovative technologies by soft lithography and detection by optical diffraction free of labeling will be build up. This development will represent a major breakthrough in bringing the microarray to the Market diagnosis by reducing its manufacturing costs, simplification of the reading system and speed in acquiring information. It will be used to design a first pre-prototype biochips to test the prediction of breast cancer carrying the biomarker genes previously identified and validated by 'classical' microarray methods. Because of its simplicity, robustness , and low cost it will be made available to clinical laboratories, and this new type of microarray is expected to fully enter into personalized medicine and help the clinician and oncologist to determine the most appropriate treatment for cancer and, more broadly, it should bring the current microarray as a tool of diagnosis. This project will be in a strategic context for the integration of converging technologies BIO-NANO-INFO in the field of Life Sciences in making the best use of potential public and private research for economic development regionally and nationally. This project covers both the component 'Experimental development' (developing a new technology for manufacturing biochips generic, up to the market between 2 and 4 years) and 'Industrial research' (pre-clinical research with the ability develop a new test this prediction based on DNA microarray previously developed and may lead to the market within 5 to 10 years). In addition, this project fits perfectly with the thematic focus 3 “Tools and innovative products in health diagnosis” and focus theme 4 "Technology Tools".